GlassScriptPhysician profile
Dianne Hall
NPI 1174906416
$1,570.53
in general payments reported to CMS, 2019-2025
23 companies · $805 in 2025
The $805 reported for 2025 was more than what 83% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.52 · 2022: $108 · 2023: $258 · 2024: $362 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401 · Education: $24.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.42 |
| Education | $24.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $253.27 | 2023-2025 | Filspari |
| Amgen INC. | $219.71 | 2022-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $204.92 | 2022-2025 | Lokelma, Farxiga, Evusheld |
| Calliditas Therapeutics US INC. | $172.62 | 2024-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $108.99 | 2023-2025 | Jynarque |
| Vifor Pharma, INC. | $89.19 | 2022-2025 | Veltassa |
| Novo Nordisk INC | $81.12 | 2024-2025 | Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $59.17 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $53.94 | 2023-2024 | Velphoro |
| Ardelyx, INC. | $41.95 | 2024 | Ibsrela |
| Lilly USA, LLC | $35.35 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $28.96 | 2025 | |
| Kyowa Kirin, INC. | $26.99 | 2023 | |
| Opko Pharmaceuticals, LLC | $24.11 | 2023 | Rayaldee |
| W. L. Gore & Associates, INC. | $23.64 | 2024 | Gore Acuseal Vascular Graft |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $23.45 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $21.52 | 2021 | |
| Abbvie INC. | $21.45 | 2023 | |
| Alexion Pharmaceuticals, INC. | $21.21 | 2025 | Ultomiris |
| Aurinia Pharma U.S., INC. | $16.55 | 2025 | Lupkynis |
| Mckesson Medical-Surgical, INC. | $15.00 | 2021 | |
| Glaxosmithkline, LLC. | $14.26 | 2024 | Benlysta |
| Pfizer INC. | $13.16 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dianne Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.